QC
ANAB icon

Quadrature Capital’s AnaptysBio ANAB Stock Holding History

Quadrature Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,280
Closed -$1.18M – 1346
2025
Q4 		$1.18M Buy
+24,280
New +$946K 0.01% 485
2025
Q2 		– Sell
-23,508
Closed -$437K – 1027
2025
Q1 		$437K Buy
+23,508
New +$392K 0.01% 615

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Quadrature Capital's ANAB Position: Q1 2026 in Review

Quadrature Capital sold out of AnaptysBio (ANAB) in Q1 2026, closing a stake of 24,280 shares — an estimated $1.18M sold.

Quadrature Capital first reported a position in ANAB in Q1 2025 and held it in 2 quarters. The position peaked at $1.18M in Q4 2025. 208 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Quadrature Capital reported no remaining AnaptysBio position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 24,280 AnaptysBio shares in Q1 2026, an estimated $1.18M.
  • Quadrature Capital first reported a position in AnaptysBio in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's AnaptysBio position peaked at $1.18M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.